Frontiers in immunology · 2026
A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.
Клиническое исследование I фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jia Dongmei, Wang Huabing, Jiang Wei, Shen Yi, Guo Jun, Zhao Daidi, Zhang Meini, Meng Huaxing, Xue Huiru, Song Yunxing, Yao Qin, Xie Ning, Zhang Chao
Аннотация
INTRODUCTION: B001 is a recombinant humanized anti-CD20 monoclonal antibody targeting CD20+ B cells, that has demonstrated superior B cell depletion and anti-proliferative and cytotoxic effects compared to rituximab in a pre-clinical study. The present phase 1b trial assessed the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of B001 in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (NMOSD).
METHODS: This phase 1b randomized, double-blind, placebo-controlled trial screened 25 NMOSD patients (April 2022-June 2024). Twenty-two patients received intravenous B001 (350, 700 or 1,000 mg) or placebo via a 3 + 3 dose escalation design, randomized 3:1 to active drug or placebo on days 1 and 15. The primary endpoints were the occurrence of dose-limiting toxicity (DLT) and to recommend the dosage for the phase 2 trial.
RESULTS: Among 22 randomized patients (350 mg: n = 3; 700 mg: n = 8; 1,000 mg: n = 6; placebo: n = 5), 20 (90.9%) completed the study. No DLT occurred in evaluable patients. Treatment-related adverse events (TRAEs) occurred in 7/21 (33.3%) patients, including urinary tract infection (14.3%), infusion-related reactions (9.5%), abnormal blood routine tests (9.5%) and hyperlipidemia (4.8%). No TRAEs led to discontinuation, dose reduction or death. Pharmacokinetic analysis revealed that supra-proportional exposure increased at 1,000 mg vs. 700 mg. Pharmacodynamics showed sustained B cell depletion (nearly 0/μL) for 24 weeks. No NMOSD relapses occurred during the 24-week study.
CONCLUSION: B001 demonstrated favorable safety and tolerability, with 700 mg selected as the recommended phase 2 dose.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05145361, identifier NCT05145361.
METHODS: This phase 1b randomized, double-blind, placebo-controlled trial screened 25 NMOSD patients (April 2022-June 2024). Twenty-two patients received intravenous B001 (350, 700 or 1,000 mg) or placebo via a 3 + 3 dose escalation design, randomized 3:1 to active drug or placebo on days 1 and 15. The primary endpoints were the occurrence of dose-limiting toxicity (DLT) and to recommend the dosage for the phase 2 trial.
RESULTS: Among 22 randomized patients (350 mg: n = 3; 700 mg: n = 8; 1,000 mg: n = 6; placebo: n = 5), 20 (90.9%) completed the study. No DLT occurred in evaluable patients. Treatment-related adverse events (TRAEs) occurred in 7/21 (33.3%) patients, including urinary tract infection (14.3%), infusion-related reactions (9.5%), abnormal blood routine tests (9.5%) and hyperlipidemia (4.8%). No TRAEs led to discontinuation, dose reduction or death. Pharmacokinetic analysis revealed that supra-proportional exposure increased at 1,000 mg vs. 700 mg. Pharmacodynamics showed sustained B cell depletion (nearly 0/μL) for 24 weeks. No NMOSD relapses occurred during the 24-week study.
CONCLUSION: B001 demonstrated favorable safety and tolerability, with 700 mg selected as the recommended phase 2 dose.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05145361, identifier NCT05145361.